{
    "eid": "2-s2.0-85124021034",
    "title": "Immunogenicity of ChAdOx1 nCoV-19 Booster Vaccination Following Two CoronaVac Shots in Healthcare Workers",
    "cover-date": "2022-02-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Drug Discovery",
            "@code": "3002",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Booster",
        "Cellular immune response",
        "ChAdOx1",
        "CoronaVac",
        "COVID-19",
        "Healthcare worker",
        "Immunogenicity",
        "SARS-CoV-2",
        "Third dose",
        "Vaccines"
    ],
    "authors": [
        "Wisit Prasithsirikul",
        "Krit Pongpirul",
        "Tanawin Nopsopon",
        "Phanupong Phutrakool",
        "Wannarat Pongpirul",
        "Chatpol Samuthpongtorn",
        "Pawita Suwanwattana",
        "Anan Jongkaewwattana"
    ],
    "citedby-count": 5,
    "ref-count": 25,
    "ref-list": [
        "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, china",
        "Seroprevalence study of SARS-CoV-2 antibodies in healthcare workers following the first wave of the COVID-19 pandemic in a tertiary-level hospital in the south of ireland",
        "Challenges to the system of reserve medical supplies for public health emergencies: Reflections on the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in china",
        "Risk of COVID-19 among front-line health-care workers and the general community: A prospective cohort study",
        "Prevalence of SARS-CoV-2 infection in previously undiagnosed health care workers in new jersey, at the onset of the U.S. COVID-19 pandemic",
        "Seroprevalence of hospital staff in a province with zero COVID-19 cases",
        "COVID-19 seroprevalence among hospital staff and preprocedural patients in thai community hospitals: A cross-sectional study",
        "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",
        "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (coronavac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial",
        "Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers",
        "Comparison of the immunogenicity of bnt162b2 and coronavac COVID-19 vaccines in hong kong",
        "Dynamic igg seropositivity after rollout of coronavac and bnt162b2 COVID-19 vaccines in chile: A sentinel surveillance study",
        "Should a third booster dose be scheduled after two doses of coronavac? A single-center experience",
        "Immunogenicity and safety of a third dose of coronavac, and immune persistence of a two-dose schedule, in healthy adults: Interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials",
        "SARS-CoV-2 specific antibody responses after third coronavac or bnt162b2 vaccine following two-dose coronavac vaccine regimen",
        "Antibody responses to COVID-19 vaccines in older adults",
        "Coronavac induces lower neutralising activity against variants of concern than natural infection",
        "Serum neutralising activity against SARS-CoV-2 variants elicited by coronavac",
        "Reactogenicity and immunogenicity after a late second dose or a third dose of chadox1 ncov-19 in the uk: A substudy of two randomised controlled trials (cov001 and cov002)",
        "Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of chadox1 ncov-19 or bnt162b2 in the uk (cov-boost): A blinded, multicentre, randomised, controlled, phase 2 trial",
        "Immunogenicity, safety and reactogenicity of a heterogeneous booster following the coronavac inactivated SARS-CoV-2 vaccine in patients with sle: A case series",
        "Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults",
        "Intradermal chadox1 vaccine following two coronavac shots: A case report",
        "SARS-CoV-2 igg antibody response after immunization of healthcare workers with inactivated COVID-19 vaccine (coronavac) at phyathai 3 hospital",
        "Safety and immunogenicity of coronavac and chadox1 against the SARS-CoV-2 circulating variants of concern (alpha, delta, beta) in thai healthcare workers"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60032499",
            "affilname": "Harvard T.H. Chan School of Public Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032499",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60020543",
            "affilname": "Bumrungrad International Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60020543",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "60011947",
            "affilname": "Thailand National Center for Genetic Engineering and Biotechnology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011947",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Baltimore",
            "@id": "60006183",
            "affilname": "Johns Hopkins Bloomberg School of Public Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006183",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Nontaburi",
            "@id": "106545448",
            "affilname": "Bamrasnaradura Infectious Diseases Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/106545448",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "National Research Council of Thailand"
    ]
}